Fibrosis constitutes a dominant substrate for AF [82], and circulating fibrotic biomarkers—such as fibroblast growth factor-23 and galectin-3—track with AF burden and features of AIC [83,84,85,86,87,88]. The gene discussed is FGF23; the disease is atrial fibrillation.